Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. - Wikidata - awgldk - TriplyDB

Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.

Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.

http://www.wikidata.org/entity/Q46106546

about

RNA vaccines in cancer treatment Translatability scoring in drug development: eight case studies CTLA-4 blockade: therapeutic potential in cancer treatments Melanoma immunotherapy dominates the field The European Organization for Research and Treatment of Cancer perspective on designing clinical trials with immune therapeutics Immunotherapy for lung cancer Tremelimumab: research and clinical development Predictive factors for immunotherapy in melanoma Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis Stem cells and targeted approaches to melanoma cure Immune Checkpoint Blockade in Cancer Therapy PD-1 as an emerging therapeutic target in renal cell carcinoma: current evidence CTLA-4 blockade in tumor models: an overview of preclinical and translational research New immunotherapies targeting the PD-1 pathway The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment The blockade of immune checkpoints in cancer immunotherapy Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma Modulation of cell signaling networks after CTLA4 blockade in patients with metastatic melanoma CTLA4 blockade broadens the peripheral T-cell receptor repertoire Cytokine working group study of lymphodepleting chemotherapy, interleukin-2, and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma: clinical outcomes and peripheral-blood cell recovery.Inhibitors of B7-CD28 costimulation in urologic malignancies.Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study Antibody therapies for melanoma: new and emerging opportunities to activate immunity (Review).Trends in cancer immunotherapy Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study Novel anti-melanoma treatment: focus on immunotherapy.Multifunctional T-cell analyses to study response and progression in adoptive cell transfer immunotherapy Immune checkpoint inhibitors in NSCLC.The consequence of immune suppressive cells in the use of therapeutic cancer vaccines and their importance in immune monitoring GM-CSF gene-modifed cancer cell immunotherapies: of mice and men.Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.Clinical Implications of Co-Inhibitory Molecule Expression in the Tumor Microenvironment for DC Vaccination: A Game of Stop and Go.CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations Clinical Development of Immune Checkpoint Inhibitors.Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis.HSPPC-96 vaccine in metastatic melanoma patients: from the state of the art to a possible future.Targeting precision medicine toxicity: recent developments.Natural killer T cells in advanced melanoma patients treated with tremelimumab

P2860

Q21296852-BB783FC8-B155-435C-BBF4-C96C26914B46 Q22241760-5F36CD9A-ED98-48A1-B217-9CC03B70B6CD Q24622666-82C086F7-EB38-4740-AF60-D55CBD47DAB7 Q26738671-E8976A6C-2942-49C5-B155-A993C21FE2FA Q26738677-64E7E4AB-8317-4586-873C-7EA720DA72BE Q26751254-6678862C-9246-41A1-9003-5CE0C4519690 Q26752822-66F5A44B-64C7-4BA2-9901-BD0EA34DC3AD Q26778765-F08A61A6-35BC-4CB8-BD86-1C8B9668C7AF Q26785746-81C62D40-04E3-4C45-9D9F-98439C4D2899 Q26825014-547B5215-2EF0-4664-8F34-8A46F741033D Q26830509-6B7E1F4F-73ED-4B7B-9638-F1123B56DB64 Q26865789-F647A985-8159-4236-B623-E0203D95FCEF Q26992295-276EF05B-0C9C-4C33-8894-1B795A34E0B5 Q27010018-FDAE061A-3C78-467C-B584-2C302A89CF63 Q27022789-DC020079-4DD6-4FCA-9536-CBF7CA323696 Q27860852-4219D9B4-A372-4FEC-ABCB-93CB9DD273E7 Q27860857-C9F8636D-AE42-4B35-816A-DF256B178704 Q28307216-8523FEAA-718F-4E13-B6FC-040988830097 Q28749278-2F3225F1-12E9-4DAE-8BA8-40902EBD2CAD Q33560753-E5189538-FD9B-4C46-B6C4-9AB3981D8EC8 Q33710973-10517B80-B344-4504-A33E-F80A73C797FB Q33827752-85FD132C-6A58-4482-9AA4-8BA2E755A609 Q33880042-D4EB34E5-6C09-490C-BFE2-4530F9FF0F6B Q34000700-19A263AB-B27D-4989-888F-C3A0FEC67D64 Q34052702-C9DE8972-AC8B-44EF-99AB-C5D0ADF62411 Q34111789-46797828-B7A3-41DB-9994-B5C85A18BAB4 Q34194680-2EB1707A-DA59-4259-AE61-378AB0487F4C Q34309404-6EA6AAD9-892A-4A96-BF77-F6F13ED8CE14 Q34334598-4769E6B9-E44D-4544-B0F4-A4F7C014325C Q34437570-D9C1F13A-10D7-416D-A121-28BC7E963FE7 Q34557531-0088968B-1FF0-4ACF-9455-4FD4823D448E Q34591128-57804572-44C6-483B-963B-7575C15DDC33 Q34647109-922199EE-059E-453F-9272-DB9FA4645C88 Q34658452-BCD93442-ADE3-46C0-9B70-BBC5C0D506E0 Q34667662-4F56A7AE-E764-46C8-826B-2E8C1EBC252F Q34671498-7292B540-4053-471D-98F4-EEAEC93274DB Q34720087-99FED9A5-0AFA-4149-BC5B-5C436961B3FA Q35009889-59F947CB-9CCF-4C95-8FB7-454F116DAA1A Q35019470-3532B59F-055E-4562-AAB2-E2479A154886 Q35027661-2AFE144A-12C8-4567-B7E6-F3BBBE51EC93

P2860

Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.

http://www.wikidata.org/entity/Q46106546

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh-hant

name

Antitumor activity in melanoma ...... onoclonal antibody CP-675,206.

@en

Antitumor activity in melanoma ...... onoclonal antibody CP-675,206.

@nl

type

label

Antitumor activity in melanoma ...... onoclonal antibody CP-675,206.

@en

Antitumor activity in melanoma ...... onoclonal antibody CP-675,206.

@nl

prefLabel

Antitumor activity in melanoma ...... onoclonal antibody CP-675,206.

@en

Antitumor activity in melanoma ...... onoclonal antibody CP-675,206.

@nl

P1433

Q46106546-94ABA4C6-0408-4EBD-847A-CD4DCF7A8FDA

P1476

Q46106546-97C54B4B-A118-4686-AA2B-70F69E1E8C20

P2093

Q46106546-0DBDE10A-2FDD-4831-9C83-7E1B286E2B8F

Q46106546-3B1193E0-F98A-4223-A9DF-1DCB417E2617

Q46106546-55EE16B8-B887-4931-B402-D526FB4ACBB4

Q46106546-7038FBEF-79EA-4872-8AE1-E52B3D084ACE

Q46106546-861FB96E-39EE-424E-9697-6728ECF86FE3

Q46106546-8A16A8E6-9B5B-43C3-B4BF-76681E9BC0F2

Q46106546-9ADFD50D-ECA9-40DB-B39E-DE5851FCC76F

Q46106546-9C1C45F3-22DA-4B1F-9E93-BEF627A008EF

Q46106546-9D72F067-5251-4F12-B6C6-4652EBED253E

Q46106546-A6B62AC7-7ADF-4D90-B1D9-0BE937802FDB

P304

Q46106546-0AC103D7-75D7-4D9F-8BEC-DD27118DC786

P31

Q46106546-35CACB86-A61C-424C-871E-EBD7A85BE3CB

P356

Q46106546-ABB96D1D-FE8B-4CFA-8840-5E5083B97C4E

P407

Q46106546-65483E8D-1F2D-41C6-A4F1-17458317B063

P433

Q46106546-6CCBBD47-D631-4265-801A-14126726EF30

P478

Q46106546-ADF4DBC8-26F1-4823-A5EC-2AFC8142FD26

P50

Q46106546-35F901F4-5F39-4C23-A861-CF70AFC9FE8F

Q46106546-F1019319-FB09-42C2-8859-F8FE4190C2CA

P577

Q46106546-500DE691-A226-42FD-962F-759BD6EA5DA1

P698

Q46106546-174F4D4E-F87F-4BE1-A65E-4521C7FDF8BD

P921

Q46106546-45070C9D-237B-4C1F-ACD6-02025004291A

Q46106546-E1E4A93F-19F3-4A52-9B35-A6E641E669A9

Q46106546-F43FF460-3028-4F9A-B73F-2A4C8FBBB848

P356

JCO.2005.01.109

P1433

Journal of Clinical Oncology

P1476

Antitumor activity in melanoma ...... onoclonal antibody CP-675,206.

@en

P2093

Amarnath Sharma

http://www.w3.org/2001/XMLSchema#string

Antoni Ribas

http://www.w3.org/2001/XMLSchema#string

Cecile A Bulanhagui

http://www.w3.org/2001/XMLSchema#string

Charla A Parker

http://www.w3.org/2001/XMLSchema#string

Dmitri Pavlov

http://www.w3.org/2001/XMLSchema#string

Elisabeth Seja

http://www.w3.org/2001/XMLSchema#string

Gabriel Lopez-Berestein

http://www.w3.org/2001/XMLSchema#string

James M Reuben

http://www.w3.org/2001/XMLSchema#string

Jesus Gomez-Navarro

http://www.w3.org/2001/XMLSchema#string

John A Glaspy

http://www.w3.org/2001/XMLSchema#string

P304

8968-8977

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2005.01.109

http://www.w3.org/2001/XMLSchema#string

P407

P433

35

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P50

Begoña Comin-Anduix

P577

2005-10-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16204013

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial